Item 7.01 Regulation FD Disclosure.
On
· Heart disease including hypertension utilizing CBD; · Reduced-risk methods of delivering non-combusted nicotine; · Improving antiviral drug delivery for applications that include Covid-19, influenza, herpes, hepatitis and AIDS; and · Hemp-based CBD business-to-business ("B2B") applications for non-pharmaceutical consumer and therapeutic or medicinal products and prospective pharmaceutical indications beyond hypertension.
Item 9.01 Financial Statements And Exhibits.
Exhibit No. Description 99.1 Press Release issuedNovember 5, 2020 2
© Edgar Online, source